PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 11921435-7 2002 Further differences in the safety profiles of these agents arise because the oxidative metabolism for each agent occurs by distinct cytochrome pathways: troglitazone and pioglitazone involve CYP 3A4 and CYP 2C8 whereas rosiglitazone is principally metabolized by CYP 2C8. Pioglitazone 170-182 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 191-198 11921435-8 2002 CYP 3A4 is involved in the metabolism of over 150 drugs, hence the potential for drug interactions with troglitazone and pioglitazone is much greater than with rosiglitazone. Pioglitazone 121-133 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 0-7 18783297-9 2008 Using this equation, the ICCYP3A4 was calculated for seven inducers (bosentan, carbamazepine, efavirenz, phenytoin, pioglitazone, rifampicin [rifampin], and St John"s wort [hypericum]) on the basis of the reduction in the AUC of a coadministered standard substrate of CYP3A4, such as simvastatin, in ten DDI studies. Pioglitazone 116-128 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 27-33 22942318-6 2012 Use of this two-step statistical evaluation is illustrated with the examination of five drugs of varying capabilities to inactivate CYP3A4: ketoconazole, erythromycin, raloxifene, rosiglitazone, and pioglitazone. Pioglitazone 199-211 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 132-138 27599706-4 2017 METHODS: This study predicted the magnitude of the DDI between efavirenz, an inducer of CYP3A4 and inhibitor of CYP2C8, and dual CYP3A4/CYP2C8 substrates (repaglinide, montelukast, pioglitazone, paclitaxel) using a physiologically based pharmacokinetic (PBPK) modeling approach integrating concurrent effects on CYPs. Pioglitazone 181-193 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 129-135 26296069-1 2015 PURPOSE: Repaglinide and pioglitazone are both CYP2C8 and CYP3A4 substrates. Pioglitazone 25-37 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 58-64 12463723-0 2002 Pioglitazone: effect on CYP3A4 activity. Pioglitazone 0-12 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 24-30 16867170-0 2006 Pioglitazone is metabolised by CYP2C8 and CYP3A4 in vitro: potential for interactions with CYP2C8 inhibitors. Pioglitazone 0-12 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 42-48 16447051-10 2006 CONCLUSIONS: Pioglitazone does not increase the plasma concentrations of repaglinide, indicating that the inhibitory effect of pioglitazone on CYP2C8 and CYP3A4 is very weak in vivo, probably due to its extensive plasma protein binding. Pioglitazone 127-139 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 154-160 16283275-1 2005 OBJECTIVE: Our objective was to study the effects of gemfibrozil on the pharmacokinetics of pioglitazone and the active compounds, which are all the substrates of CYP2C8 and CYP3A4. Pioglitazone 92-104 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 174-180 15900286-1 2005 BACKGROUND AND OBJECTIVE: The thiazolidinedione antidiabetic drug pioglitazone is metabolized mainly by cytochrome P450 (CYP) 2C8 and CYP3A4 in vitro. Pioglitazone 66-78 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 134-140 12642470-4 2003 While troglitazone was the most potent, rosiglitazone and pioglitazone generally exceeded troglitazone in absolute CYP3A4 activity achieved at concentrations > or =10 microM. Pioglitazone 58-70 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 115-121 12642470-6 2003 Microarray analysis revealed rifampin > troglitazone > pioglitazone > rosiglitazone in terms of CYP3A4 mRNA induction potential with 10 microM compound. Pioglitazone 61-73 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 105-111 17201456-6 2007 CYP2C8 and CYP3A4 are the main isoenzymes catalysing biotransformation of pioglitazone (as with troglitazone), whereas rosiglitazone is metabolised by CYP2C9 and CYP2C8. Pioglitazone 74-86 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 11-17 17214065-1 2006 BACKGROUND: Pioglitazone is a thiazolidinedione compound used in the treatment of type 2 diabetes, metabolized mainly by CYP2C8 and CYP3A4. Pioglitazone 12-24 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 132-138 16867170-3 2006 The metabolism of pioglitazone by CYP1A2, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, CYP2E1, CYP3A4 and CYP3A5 was investigated using human recombinant CYP isoforms. Pioglitazone 18-30 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 91-97 16867170-4 2006 In particular, the inhibitors of CYP2C8, but also those of CYP3A4, markedly inhibited the elimination of pioglitazone and the formation of M-IV by HLM. Pioglitazone 105-117 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 59-65 16867170-9 2006 In conclusion, pioglitazone is metabolised mainly by CYP2C8 and to a lesser extent by CYP3A4 in vitro. Pioglitazone 15-27 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 86-92 16447051-0 2006 Pioglitazone, an in vitro inhibitor of CYP2C8 and CYP3A4, does not increase the plasma concentrations of the CYP2C8 and CYP3A4 substrate repaglinide. Pioglitazone 0-12 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 50-56 16447051-1 2006 OBJECTIVE: Pioglitazone, a thiazolidinedione antidiabetic, inhibits cytochrome P450 (CYP) 2C8 and CYP3A4 enzymes in vitro. Pioglitazone 11-23 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 98-104 15900286-12 2005 CYP2C8 appears to be of major importance and CYP3A4 of minor importance in pioglitazone metabolism in vivo in humans. Pioglitazone 75-87 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 45-51 16372821-14 2005 CYP2C8 and CYP3A4 are the main enzymes catalysing biotransformation of the thiazolidinediones troglitazone and pioglitazone, whereas rosiglitazone is metabolised by CYP2C9 and CYP2C8. Pioglitazone 111-123 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 11-17 12463723-1 2002 Clinical studies demonstrate CYP3A4 enzyme induction with troglitazone, a thiazolidinedione derivative structurally related to pioglitazone. Pioglitazone 127-139 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 29-35 12463723-2 2002 The objective of this prospective, open-label study conducted in healthy volunteers was to evaluate the influence of multiple-dose pioglitazone therapy on the urinary excretion ratio of 6-beta-hydroxycortisol to cortisol, an endogenous marker of CYP3A4 activity. Pioglitazone 131-143 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 246-252